Overview
Sermorelin, also known as GHRH (1-29), is a synthetic peptide consisting of the first 29 amino acids of the naturally occurring growth hormone-releasing hormone. It retains the full biological activity of the complete 44-amino acid GHRH molecule.
Medical History
Sermorelin was previously FDA-approved under the brand name Geref for diagnostic evaluation and treatment of growth hormone deficiency in children. However, the manufacturer discontinued production for commercial reasons, though compounding pharmacies may still prepare it under physician supervision.
Mechanism of Action
Sermorelin works by binding to GHRH receptors on pituitary somatotrophs, stimulating the natural production and release of growth hormone. Key features include:
- Stimulates pulsatile GH release similar to physiological patterns
- Subject to negative feedback regulation (prevents GH excess)
- Does not bypass the bodys natural regulatory mechanisms
Research Applications
Sermorelin has been studied for:
- Pediatric growth hormone deficiency
- Adult growth hormone decline
- Body composition changes
- Sleep quality improvements
Administration
When prescribed, sermorelin is typically administered via subcutaneous injection, often at bedtime to coincide with natural GH release patterns.
Advantages
Compared to exogenous growth hormone, sermorelin:
- Stimulates natural GH production
- Maintains pituitary function
- Has a better safety profile for long-term use
- Is less likely to cause GH excess